Tech Company Financing Transactions
Allogenetics Funding Round
NBank Capital, Carma Fund and private investors participated in a $4.4 million Series A venture round for Allogenetics. The financing round was announced on 9/9/2026.
Transaction Overview
Company Name
Announced On
9/9/2026
Transaction Type
Venture Equity
Amount
$4,400,000
Round
Series A
Investors
NBank Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support its lead program, ALG-115, through IND-enabling studies toward clinical evaluation in lung transplantation.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Feodor-Lynen-Str. 5
Hannover-Buchholz-Kleefeld, 30625
Germany
Hannover-Buchholz-Kleefeld, 30625
Germany
Phone
Undisclosed
Website
Email Address
Overview
Allogenetics GmbH offers a completely new solution to the problem of organ rejection after transplantation. The Allogenetics approach is a unique first-in-class therapeutic as it treats the transplant instead of paralyzing the patient's immune system. This innovation offers a new dimension in organ transplantation: Invisible organs instead of lifelong immunosuppression.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Oliver Ernst
Chief Marketing Officer
Jeroen Rovers
Chief Scientific Officer
Constanca Figueiredo
Founder
Rainer Blasczyk
VP - Bus. Development
Frank Schnieders
VP - Regulatory Affairs
Bettina Rohde
Browse more venture capital transactions:
Prev: 9/9/2026: Dynamic Creatures venture capital transaction
Next: 9/9/2026: Rebaba venture capital transaction
Share this article
News on VC Transactions
We record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs